UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
[GRAPHIC OMITTED]
FORM 12b-25
NOTIFICATION OF LATE FILING
333-61610
(Commission File Number)
(Check One): [_] Form 10-KSB [_] Form 20-F [_] Form 11-K [_] Form 10-D
[X] Form 10-QSB [_] Form N-SAR [_] Form N-CSR
For Period Ended: June 30, 2006
|_| Transition Report on Form 10-K
|_| Transition Report on Form 20-F
|_| Transition Report on Form 11-K
|_| Transition Report on Form 10-Q
|_| Transition Report on Form N-SAR
For the Transition Period Ended: _________________________
--------------------------------------------------------------------------------
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
--------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
--------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
Brainstorm Cell Therapeutics Inc.
Full Name of Registrant
Former Name if Applicable: Golden Hand Resources Inc.
110 East 59th Street, 25th Floor
Address of Principal Executive Office (Street and Number)
New York, NY 10022
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
(a) The reason described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report
on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed
|X| due date; or the subject quarterly report or transition report on
Form 10-Q or subject distribution report on Form 10-D, or portion
thereof, will be filed on or before the fifth calendar day following
the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III -- NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR,
N-CSR, or the transition report or portion thereof, could not be filed within
the prescribed time period.
The registrant's Quarterly Report on Form 10-QSB for the three months ended June
30, 2006 could not be filed by the prescribed due date of August 14, 2006
because the registrant has not yet finalized its financial statements for such
three month period due to an internal ongoing review, the outcome of which may
affect the financial statements of the registrant that are to be included in the
registrant's Quarterly Report on Form 10-QSB. Accordingly, the registrant is
unable to file such report within the prescribed time period without
unreasonable effort or expense. The registrant's Quarterly Report on Form 10-QSB
will be filed on or before the fifth calendar day following the prescribed due
date.
PART IV-- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
David Stolick (212) 557-9000
---------------------- ---------- ------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s). |X| Yes |_| No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
|_| Yes |X| No
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Brainstorm Cell Therapeutics Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: August 15, 2006
By: /s/ Yoram Drucker
--------------------------------
Yoram Drucker
Chief Operating Officer